Ainos (AIMD) investor relations material

Executive summary

• Focused on commercializing AI Nose, an AI-driven scent digitization platform, and advancing VELDONA® immune therapeutics, with 2026 priorities on industrial deployments and partner-led expansion.

• Continued execution of commercialization strategy for AI Nose across semiconductor, industrial, healthcare, and robotics markets, with deployments expanding in 2026.

• AI Nose accumulated 613 million industrial smell data records since December 2025, strengthening the Smell AI Platform.

• Shifted operational focus from healthcare-adjacent applications to industrial environments, especially semiconductor and robotics sectors.

• Focus on expanding real-world applications, strategic collaborations, and operational efficiency to support long-term growth.

Financial highlights

• Q2 2026 revenue was $152, down 97% year-over-year; H1 2026 revenue was $110,870, down from $19,170 year-over-year, mainly due to lower sales of VELDONA pet supplements and AI Nose programs.

• Q2 2026 net loss was $4.6M, up 12% year-over-year; H1 2026 net loss was $7.1M, slightly improved from $7.4M year-over-year.

• Operating expenses for Q2 2026 were $4.4M, up from $3.7M in Q2 2025, driven by higher SG&A costs.

• Cash and cash equivalents at June 30, 2026 were $1.42M, down from $2.2M at year-end 2025.

• Total assets decreased to $19.6M as of June 30, 2026, from $20.9M at December 31, 2025.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for at least the next twelve months as product development and commercialization efforts continue.

• Broader revenue generation opportunities anticipated in the second half of 2026 as commercialization expands.

• Plans to fund operations through existing cash, equity, and debt financing, but substantial doubt exists about the ability to continue as a going concern.

• Management is focused on disciplined capital allocation and operational efficiency.